Transgenic mice that expressed antisense interleukin-3 (AS-IL-3) RNA were generated and exhibited either a B-cell lymphoproliierative syndrome or progressive neurologic dysfunction. Each syndrome occurred in the founder or progeny mice of three separate transgenic lines. The lymphoproliferative process involved the accumulation, within peripheral lymphoid organs, of B220'/slgM-pre-B cells that had immunoglobulin (lg) genes predominantly in germline configuration and expressed A5 and Rag-l transcripts.
NTERLEUKIN-3 (IL-3) is a pleiotropic cytokine that is
produced predominantly by mitogen or antigen-stimulated T lymphocytes. IL-3 was initially defined by its ability to induce the enzyme 20-CY-hydroxysteroid dehydrogenase in cultures of ndnu splenic lymphocytes.' Subsequently, IL-3 was shown to stimulate the in vitro proliferation and differentiation of pluripotent hematopoietic progenitor cells of the granulocyte, macrophage, eosinophil, erythroid, and megakaryocyte lineages.' In vivo administration of pharmacologic doses of recombinant IL-3 to mice results in stimulation of red blood cell, white blood cell, and platelet prod~ction.~ In addition, overexpression of the IL-3 gene in hematopoietic progenitors via retroviral transduction of bone marrow cells results in a nonneoplastic myeloproliferative syndrome in v~v o .~,~ Despite these well-defined in vitro and in vivo activities, the role of endogenous IL-3 in hematopoiesis is unclear. Athymic mice and humans have normal hematopoiesis,6 and IL-3 is not detectable in serum or urine under steady-state or hematologically-perturbed condition^.^.'
The role that IL-3 plays in lymphopoiesis is also unclear. Recent experiments have shown that, while IL-3 cannot directly induce the in vitro differentiation of lymphoid precursors from multipotent bone marrow progenitors,' it can support the in vitro proliferation of bone marrow-derived clones representing an intermediate stage of development between hematopoietic stem cells and pro-B or pro-T lymphocyte progenitors." IL-3 has also been shown to support the in vitro growth of defined populations of lymphoid precursors, and IL-3-dependent clones with pro-B, pre-B, and pro-T cell characteristics have been established from fetal liver and bone marrow.""6 In vivo administration of IL-3 in mice fails to stimulate T or B lymphopoiesis but enhances the humoral immune response to T-cell-dependent antigens." IL-3 also has a stimulatory effect on both the proliferation and differentiation of mature activated B cells in ~i t r o . '~"~ The emergence of Epstein-Barr virus (EBV)-transformed B-cell lines in vitro from the mononuclear cells of EBV-infected patients is inhibited by IL-3,'' but L 3 can act as a growth factor for various B-cell malignan~ies.~"~~ In addition to its production by T lymphocytes, L -3 mRNA has also been detected in neurons and astrocytes at discrete sites within the cerebellum and ~erebrum.'~ The IL-3 produced by activated brain-derived astrocytes or by cultured rat C6 glioma cells can stimulate the growth and differentiation of microglial ~e l l s ,~~~'~ the macrophages of the central nervous system (CNS). IL-3 has also been shown to have trophic activity for central cholinergic neurons both in vitro and in vivo.*' These findings suggest that IL-3 could be an important regulatory molecule in the development or maintenance of the CNS.
The establishment of mice exhibiting a complete or diminished capacity for IL-3 production would provide a means for addressing the role of IL-3 in hematopoietic, immune, and neurologic processes. The use of stably expressed antisense RNA sequences has been shown by ourselves and others to be a useful strategy for inhibiting the production of target molecules both in vitro and in vivo.28"' Antisense inhibition provides a means for downmodulating normal cytokine production in vivo, and this can be achieved in specific cell types via tissue-specific promoters. Antisense strategies are in contrast to the complete loss of function in every cell of the mouse that is achieved as a consequence of targeted disruption of a gene through homologous recombination. The physiologic consequences of downmodulation of cytokine production compared with a complete absence may be markedly different, particularly when a homozygous mutation of a particular gene results in a lethal phenotype in utero and prevents analysis of postnatal animals.
In the present study, we have generated transgenic mice expressing an AS-IL-3 transgene to study the consequences of a decreased capacity for IL-3 production in vivo. We previously demonstrated that stably transfected T-cell clones expressing high levels of antisense granulocyte-macrophage colony-stimulating factor (GM-CSF) RNA exhibited a significant inhibition of GM-CSF production,*' suggesting that a similar expression strategy might allow for downmodulation of IL-3 production in vivo. We describe the generation of transgenic mouse lines expressing AS-IL-3 transcripts, and exhibiting evidence of a diminished capacity to produce IL-3. The development of a B-cell lymphoproliferative syndrome or neurologic dysfunction in three AS-IL-3 transgenic lines emphasizes the utility of antisense downmodulation as a means of elucidating subtle functions of cytokines in vivo and supports a role for endogenous IL-3 in immune and neurologic function.
MATERIALS AND METHODS

Construction of the AS-IL-3 transgene.
A 990 bp fragment, corresponding to the full-length murine IL-3 cDNA was generated by polymerase chain reaction (PCR). This fragment was subcloned in the antisense orientation, with a fragment containing a 250 bp B 19 parvovirus promoter fragment:' into the pLTN13' plasmid containing human P-globin gene sequences from the intragenic BamHI site to the 3' flanking BglII site. The B19-AS-IL-3-P-globin transcriptional unit was excised from pLTNI, shuttled through a pUC derivative, and the final AS-IL-3 expression vector was generated by subcloning this transcription unit into a vector containing the 5.5 kb T-cell dominant control region from the 3' end of the human CD2 gene.34
Transgenic mice. Fertilized eggs were isolated from superovulated WB/N female mice mated to CB6/F,J males 12 hours earlier. The 8.3 kb AS-IL-3 transgene was excised from its base plasmid, and microinjected into the male pronucleus of fertilized eggs by standard technique^.'^ Transgenic mice were screened by PCR analysis using standard DNA amplification conditions (Perkin-Elmer Cetus, Nonvalk, CA). A 620 bp transgene-specific fragment was amplified from 1 pg tail DNA using a 5' primer in the B19 promoter sequence (gctctttctttctgggctgct) and a 3' primer in the AS-IL-3 coding sequence (gaagctcccagaacctgaac). PCR reactions were carried out using the following conditions: 40 cycles at 95°C for 1 .5 minutes, 60°C for 2 minutes, and 72°C for 3 minutes. Amplification products were run on agarose gels and visualized by ethidium bromide staining.
Pathologic analysis. Animals were sacrificed by cervical dislocation and organs were fixed in 10% formalin in phosphate buffered saline (PBS) for histologic analysis. Thin sections of paraffin-embedded tissues were stained with hemotoxylin-eosin. Peripheral blood smears were stained with Wright's Geimsa.
Preparation of RNA and analysis by reverse transcriptase PCR. RNA was extracted from whole organs using the guanidinium isothiocyanate method,36 and from sorted cell populations and cultured cells using a modification of the RNAzol B method (CinnaBiotecx, Friendswood, TX). RNA samples were treated with 0.1 UIpL of RQI DNase 1 (Promega, Madison, WI) in 50 mmol/L Tris-HCL (7.5), 1 mmoln EDTA, 10 mmol/L MgC12, and 2 mmol/L vanadyl ribonucleoside complex (BRL, Gaithersburg, MD) for 1 hour at 37°C.
Reverse transcription of RNA, and PCR amplification of cDNA was performed using the conditions described in the GeneAmp RNA PCR kit (Perkin-Elmer Cetus) with the following modifications. Reverse transcription was carried out on 0.2 pg of RNA using 2.5 U/ pL Superscript RNase H-reverse transcriptase (Gibco BRL, Gaithersburg, MD), 1 U/pL RNasin ribonuclease inhibitor (Promega), and 2.5 mmoVL random hexamers in a final volume of 20 pL. For PCR amplification, the 20 pL cDNA reaction was amplified in a final volume of 80 pL in the presence of 0.3 pL 32P-dCTP (3,000 Ci/ mmol), and 0.15 pmol/L of each of the following sequence specific primers. AS-IL-3-specific primers were 5"gtctagaggctagcactgtc and 3'-cagggcattagccacaccagcca, P-actin-specific primers were 5'-cattgtgatggactccggagacgg and 3'-catctcctgctcgaagtctagagc, AS-specific primers were 5"cagagtaggacagactctgg and 3"gaggattgtgctctaagaac. and Rag-l -specific primers were 5'-agctgtttgcttggccatcc and 3'-gggatctcatgccttccaag. PCR reactions were carried out using the following conditions: 30 cycles at 95°C for 1.5 minutes, 55°C for 2 minutes, and 72°C for 3 minutes. Samples were extracted once with chloroform, and 25 pL of the radiolabeled amplification products were resolved on an 8% polyacrylamide gel. Gels were dried and analyzed by autoradiography.
Analysis of Ig gene rearrangement. Analysis of Ig gene rearrangement at the heavy chain locus was carried out by PCR as described by Hardy et aI3' using the primer sets designated 5' JH1 (5' primer cccggacagagcaggcaggtgg, 3' primer ggtccctgcgccccagaca), and 5' D,,, I (5' primer gcctggggagtcactcagcagc, 3' primer gtgtggaaagctgtgtatcccc). One hundred nanograms of DNA was amplified using standard conditions in a 100 pL PCR reaction containing 0.3 pL "P-dCTP (3,000 Ci/mmol) and each set of sequencespecific primers. PCR reactions were carried out using the following conditions: initial denaturation at 95°C for 2 minutes, followed by 20 cycles at 95°C for 1 minute, 63°C for 1.5 minutes, 72°C for 2 minutes, and a final 8-minute extension at 72°C. Samples were electrophoresed as above.
Immuno$uorescence staining, analysis, and cell sorting. Single cell suspensions were prepared from tissues, the red blood cells lysed, and 1 X IO5 washed cells were resuspended in I X PBS, 5% fetal calf serum (FCS) containing the appropriate dilution of antibody. Cells were incubated on ice and washed extensively according to standard procedure. Fluorescence activated cell sorter (FACS) analysis and sorting were done using a Coulter Epics Elite Instrument (Coulter Corporation, Hialeah, FL). The antimouse monoclonal antibodies used were as follows: anti-L3T4 (CD4) PE and anti-Lyt-2 (CD8) FITC (Becton Dickinson, San Jose, CA), anti-CD3e FITC (Boehringer Mannheim, Indianapolis, IN), anti-Mac-l FITC (Caltag, San Francisco, CA), anti-CD45RD3220 PE, clone RA3-6B2, anti-Gr-l FITC, anti-CD32 FITC, anti-IgM FITC, allotype specific anti-IgD", anti-IgDh, and anti-IgD' FITC, and all appropriate FITCor PE-conjugated Ig isotype controls (Pharmingen, San Diego, CA).
In vitro stimulation of spleen cell suspensions and analysis of supernatants for the presence of IL-3. Single cell suspensions were prepared from mouse spleens and cells were cultured at 1 X 10' cells/mL in RPM1 (Gibco BRL) containing 10% FCS, 5 X IO-' mol/ L 2-mercaptoethanol (Sigma, St Louis, MO), either in the presence or absence of Conconavalin A (Sigma), at a concentration of I O pg/ mL for 48 hours. Supernatants were harvested and analyzed by enzyme-linked immunosorbent assay (ELISA) for the presence of IL-3 as previously described.3x
Oligonucleotides. Oligonucleotides were synthesized using an Applied Biosystems 380B DNA Synthesizer (Foster City, CA) and are shown written 5' to 3'
RESULTS
Experimental design and the observation of two distinct abnormal phenotypes in AS-IL-3 transgenic mice. We used a strategy similar to one used to inhibit GM-CSF production in a stably transfected T-cell line in vitro" to achieve constitutive, high-level expression of antisense IL-3 transcripts in T cells in vivo. The AS-IL-3 transgene (Fig l) The percentage of F1 and F2 animals, among all transgenic progeny, that developed the lymphoproliferative syndrome or neurologic dysfunction was 17% and 6%, respectively, in the 244 line, compared with 39% and 61%, respectively, in the 241 line. Animals from the 241 line also developed the syndromes earlier (3 to 6 months) than did animals from the 244 line (6 to 12 months).
AS-IL-3 transgenic mice develop a fatal lymphoproliferative syndrome defined by B220+/sIgM-pre-B cells. In both the 241 and 244 transgenic lines we observed an identical fatal process, presenting between 3 and 12 months of age and characterized by marked splenomegaly and peripheral adenopathy. Histopathologic analysis of the spleens and lymph nodes of affected animals showed complete effacement of the normal architecture by cellular infiltrates of immature-appearing, mitotically-active round cells (Fig 2A-C) . The peripheral blood smear shown in Fig 2D illustrates the lymphoblast morphology of these abnormal cells during the late leukemic phase that develops in these mice. These cells could also be found in the bone marrow and thymus late in disease. However, in animals killed earlier in the process, these organs did not show evidence of involvement. The aggressive nature of this process was further demonstrated by the marked infiltration seen around the spinal cord and between skeletal muscle fibers (Fig 2E,F) , leading to hind limb paralysis secondary to spinal cord compression in several animals.
The lymphoblasts from the spleen and lymph nodes of affected animals were shown by immunofluorescence staining to be strongly positive for the B220 surface antigen that is characteristic of the B-cell lineage. However, these cells did not express detectable levels of the mature B-cell surface antigens IgM, IgD, or CD32. These cells were negative for the mature T-cell surface antigens CD4, CD8, C D~E , and the a/PTcR, as well as for the Mac-l and Gr-l myeloid surface antigens (Fig 3A and data not shown) . Figure 3A illustrates a representative two color FACS profile of lymph node cells stained with anti-B220 and anti-IgM, and demonstrates that approximately 90% of these cells express B220 in the absence of sIgM. In contrast, normal lymph nodes from unimmunized mice are comprised of approximately 60% mature T cells and a lower percentage of mature B cells that coexpress B220 and sIgM. The marked alteration in the absolute number and phenotype of peripheral B cells in AS-IL-3 transgenic animals with the lymphoproliferative syndrome was not accompanied by detectable alterations in the absolute number of peripheral T cells, despite the fact that only 0.2% of the cells in the abnormal lymph nodes were CD3eexpressing T cells (data not shown).
To further evaluate the maturational stage of the B220+/ sIgM-lymphoblasts, we determined the status of Ig gene rearrangement at the heavy chain locus via a PCR strategy involving amplification of sequences present in germline DNA, but lost upon rea~~angement.~' Two sets of primers were used ( Fig 3C) ; one set that amplifies a region 5' of JH1 that is lost upon D-J rearrangement, and a second set that amplifies a region 5' of the most upstream D element, D,16.] , that is lost upon V to D-J rearrangement. Figure 3B shows a titration of DNA from FVB/N liver into DNA from the plasmacytoma cell line T116.5:' illustrating the expected lack of the JH1 and fragments in the T1165 DNA and a dose-dependent increase in the intensity of amplified germline fragments with increasing concentration (0.1 % to 100%) of FVBN liver DNA. A representative amplification of DNA from the lymph nodes of two affected animals ( Fig  3B) shows that the B220+/sIgM-lymphoblasts retain both the 5' JH1 fragment and the 5' Dm16.1 fragment. Although we cannot exclude the possibility that a small percentage of determined to be in germline configuration by Southern blot these cells have undergone DHJH rearrangements at the heavy analysis (data not shown). chain locus, these data indicate that these cells retain Ig To establish if these lymphoblasts were immature B-linheavy chain genes predominantly in the germline configura-eage cells, we assayed for expression of the pre-B cell-spetion. The Ig KL chain genes and the TcR genes were also cific gene U, and the lymphoid-specific recombination-actiFor personal use only. on October 26, 2017. by guest www.bloodjournal.org From vating gene Rag-l, using reverse transcriptase PCR (RT-PCR) (Fig 4) . The mature T cell line, EL4, did not express either A5 or Rag-l tran~cripts,4'.~' while the pre-B lymphoma cell line, 702/3, expressed U,'" but not Rag-l As expected A5 and Rag-l transcripts were detected in the bone marrow, but not the spleen or brain of a nontransgenic littermate control. In contrast, we detected both transcripts in the blast-infiltrated spleen and lymph nodes of AS-IL-3 transgenic animals affected with the lymphoproliferative syndrome. Expression of these genes identifies the infiltrating lymphoblasts as pre-B I cells by the scheme of Melchers et al."
When 1 X IO' B220' cells from the lymph nodes or spleen of two animals with the lymphoproliferative syndrome were injected subcutaneously or intraperitoneally, into either nude mice or nontransgenic littermates, recipient animals did not develop detectable tumors (five nude mice and five littermates). In addition, attempts to culture these cells in vitro in the presence of soluble cytokines, including IL-7, IL-4, or IL-2, or on the S17 murine stromal cell line: demonstrated that although these cells could persist in culture for several weeks, they could not be expanded, and no immortilized lines could be obtained.
Before the development of the B-cell lymphoproliferative process, all hematologic parameters including total white blood cell count, white blood cell differential, and red blood cell count were normal and identical to nontransgenic littermates. Transgenic animals sacrificed at age 2 to 3 months, before development of any obvious disease phenotype, had normal morphology of spleen, lymph node, thymus, and all other organs as compared with nontransgenic littermates. Ig levels, as well as B-and T-cell numbers in the peripheral blood were also identical to nontransgenic littermates. No reverse transcriptase activity was detected in spleen homogenates prepared from affected or unaffected transgenic ani- that died of the B-cell lymphoproliferative syndrome. These data demonstrate the presence of AS-IL-3 transcripts in all hemopoietic organs, including spleen, lymph node, bone marrow, and thymus. Importantly, low levels of transcripts were present in the hemopoietic tissues of F0 241, in the absence of any lymphoproliferative abnormality. In the two F1 progeny, the level of expression was markedly increased with expression being greater in F1 183, the animal that had a more aggressive lymphoproliferative syndrome. Similar expression patterns were also observed in animals from the 244 F0 line (data not shown). These data indicate that the AS-IL-3 transgene is expressed in normal hemopoietic tissues. However, its expression appears to be higher in the tissues of affected animals that are infiltrated by B220'/ sIg" pre-B cells.
We further defined the expression of AS-IL-3 transcripts by FACs sorting B220' and CD3' cell populations from the thymus, spleen, and lymph nodes of both asymptomatic transgenic animals and animals with aggressive lymphoproliferation. Reanalysis of FACS sorted cells showed them to be 2 96% pure B220' or CD3' populations (data not shown). Figure 6 shows a representative AS-IL-3 RT-PCR analysis of RNA purified from sorted cell populations. The asymptomatic transgenic animal expressed the AS-IL-3 transgene in whole thymus and spleen, as well as in sorted CD3' cells and to a lesser extent in sorted B220' cells. In the animal with the B-cell lymphoproliferative syndrome AS-IL-3 transcripts were also detected in sorted CD3' cells. In addition, we observed an increase in the expression of the transgene in sorted B220' abnormal pre-B cells from the spleen and lymph nodes of the affected animal, compared with that seen in sorted B220' mature B cells from the asymptomatic animal. It is possible that the increased expression of the AS-IL-3 transgene in these pre-B cells may reflect differential regulation of transgene expression by the CD2 dominant control region in immature versus mature B-cell populations.
AS-IL-3 transcripts are expressed in the brains of animals with neurologic dysfunction. Three F0 animals (234, 241, and 244) and the progeny of two of these transgenic lines (241 and 244) developed a neurologic disorder that occurred independently of the B-cell lymphoproliferative syndrome. Animals that developed neurologic dysfunction exhibited circling behavior that progressed to ataxia and uncoordinated movement, followed by wasting and death resulting from an inability of the animal to eat or drink. The neurologic disorder was first seen in animals between 3 and 6 months of age, and was fatal within 2 to 4 weeks from the time of onset. Examination of the neurologic tissues showed no gross CNS pathology. There was no infiltration of the immature lymphoid cells seen in animals with the lymphoproliferative syndrome in the cerebrum, cerebellum, brain stem, spinal cord, or peripheral nerves of animals with neurologic dysfunction.
To determine if the AS-IL-3 transgene was expressed in the nervous system, we measured AS-IL-3 transcripts in the brains of a panel of transgenic animals using the RT-PCR assay previously described. Figure 7 shows that F0 animals 241 and 244 that died of the neurologic disorder both expressed AS-IL-3 transcripts in the brain, and that the expression level was greater in F0 241 as compared with F0 244. When several progeny of F0 241 were analyzed, both asymptomatic transgenics killed at 8 to 10 weeks of age, and neurologically affected transgenics killed at 16 to 20 weeks of age, showed expression of the transgene in the cerebrum or cerebellum.
Splenocytes from AS-IL-3 transgenic mice produce significantly decreased levels of IL-3. To determine if the AS-IL-3 transcripts could mediate antisense inhibition of IL-3 production by T cells, splenocytes from 8 to 10 week old nontransgenic and asymptomatic transgenic animals were stimulated in vitro with ConA for 48 hours, and the supernatants tested for the presence of IL-3 by an ELISA assay. In contrast to the observation that splenocytes from all nontransgenic animals produced IL-3 on stimulation, several of the asymptomatic transgenic animals produced no detectable IL-3 (Fig 8) . The average level of IL-3 produced by cells from the panel of 11 asymptomatic transgenic animals was 18.2 2 7.9 pg/mL, compared with an average level of 90.9 2 9.2 pg/mL produced by cells from the panel of eight nontransgenic animals (P 5 .OOOI). Expression of the AS-IL-3 transgene was confirmed in all asymptomatic transgenic samples by RT-PCR analysis of RNA isolated from the splenocyte cultures after 48 hours of ConA stimulation (data not shown). IL-2 production by stimulated splenocytes was also assayed via an ELISA assay, and was not significantly different between the transgenic and nontransgenic groups (data not shown). These data suggest that the AS-IL-3 transcripts present in the T cells of asymptomatic animals can effect inhibition of L-3 production, and in vivo, chronic inhibition of T-cell IL-3 production may be a predisposing mechanism in the development of the B-cell lymphoproliferative syndrome or neurologic dysfunction.
DISCUSSION
To downregulate the production of IL-3 in vivo, we generated transgenic mice that expressed antisense RNA complimentary to IL-3 mRNA sequences. Transgenic mice from three separate lines that expressed the AS-IL-3 transgene developed either of two independently occurring fatal syndromes, a pre-B cell lymphoproliferation or neurologic dysfunction. We further demonstrated that the AS-IL-3 transgene was able to effect antisense inhibition of endogenous IL-3 production by splenocytes from asymptomatic transgenic animals. Several other examples of antisense inhibition in transgenic mice in vivo have been reported. Expression of an antisense HPRT transgene was shown to inhibit endogenous HPRT expression in vivo?' and antisense RNA complementary to retroviral packaging sequences was shown to inhibit Moloney murine leukemia virus-induced le~kemia.2~ In addition, expression of a myelin basic protein antisense transgene resulted in conversion of normal behavior to shiverer in transgenic mice." The results of the present study suggest that antisense RNA inhibition may be an effective strategy for downmodulating cytokine production in vivo.
The lymphoproliferative syndrome in AS-IL-3 transgenic mice was characterized by an aggressive proliferation of B220+/sIgM-B-lineage blasts. These blast cells were likely polyclonal with respect to DHJH rearrangements at the heavy chain locus as a percentage of the cells had begun DHJH rearrangement events, but had not yet undergone VHDHJH or KL chain rearrangements. Transcripts for the pre-B cell- the in vitro proliferation of fetal liver and bone marrowderived pro-B-cell clones that contain Ig genes in germline as well as pre-B-cell clones that contain small amounts of cytoplasmic p chain." These IL-3-dependent B-cell precursors were capable of differentiating both in vivo" and in vi11-o'~ into mature Ig producing B lymphocytes, and of repopulating the precursor and mature sIg' Bcell compartment of scid While these studies show that IL-3 can support the proliferation of progenitor and precursor clones that have become committed to the B-lineage, other data has demonstrated that IL-3 cannot directly induce the in vitro differentiation of lymphoid precursors from multipotential bone marrow progenitors, and may even be inhibitory in certain model systems. Hirayama et a19,46 have shown that the development of B-lymphoid colonies in vitro from primitive bone marrow precursors does not require IL-3, and in fact, the inclusion of IL-3 in certain supportive cytokine combinations can inhibit the development of these colonies.
In AS-IL-3 transgenic mice that develop the B-cell lymphoproliferative syndrome, chronic downmodulation of IL-3 production may result in the loss of a negative regulatory cytokine signal that influences the expansion of B-lineage precursor pools.
During B-cell development the proliferation of B-cell pre-2707 cursors requires their direct association with stromal elements in the bone marrow microenvironment."~5' It ha:, been suggested that TL-3 might function indirectly to modulate the interaction of stromal elements with proliferating B-cell precursors by inducing the differentiation of an accessory cell type, such as the macrophage.s2 Macrophages produce cytokines that modulate the proliferation and differentiation of B-cell precursors, and eliminate immature B cells bearing self-reactive Ig molecules that are destined to undergo apoptosis. In AS-IL-3 transgenic mice that develop the Bcell lymphoproliferative syndrome, decreased local production of IL-3 by T cells in the bone marrow might perturb the normal growth, differentiation, and censoring signals that regulate B lymphopoiesis, allowing highly proliferative pre-B cells to exit the bone marrow and continue proliferating within the peripheral lymphoid organs. While the two mechanisms suggested may play a role in the development of the pre-B-cell lymphoproliferative syndrome, additional studies are needed to further clarify the role of IL-3 in de novo B lymphopoiesis and to understand the extent of cellular dysfunction in the bone marrow of the AS-IL-3 mice.
Based on the known cooperativity between dysregulated growth factor signaling and oncogene activation, it is possible that loss of growth control in the precursor B-cell compartment due to downmodulation of IL-3 could represent an initiating event that predisposes these cells to secondary transformation. Within the B-lineage differentiation pathway, the highly proliferative pro-B and pre-B cells are particularly susceptible to transformation, as is evidenced by the ability of the abelson murine leukemia virus to transform pre-B cells,"~5s and the presence of pre-B-cell tumors in transgenic mice expressing the myc oncogene linked to the Ig enhancer.'6 We could not assess if a secondary clonal event had occurred in the proliferative B lymphoblasts from AS-IL-3 transgenic mice due to their primarily germline lg gene configuration. These B220+/sIgM-pre-B cells were not tumorogenic, and did not exhibit the property of autonomous growth in vitro, suggesting that they had not been transformed via oncogenic mutation. The variable and relatively late onset of the syndrome however, suggests that some secondary event may have been necessary for the development of this lymphoproliferative disorder.
The neurologic dysfunction appearing in three AS-IL-3 founder animals and many transgenic progeny supports the hypothesis, based on in vitro data, that IL-3 may play a role in the maintenance of normal neural processes. Asymptomatic transgenic animals killed at 8 to 10 weeks of age, before the development of any clinical neurologic syndrome, expressed AS-IL-3 transcripts in CNS tissue at levels similar to that seen in animals killed after the development of ataxia and other abnormalities. This observation suggests that prolonged expression of antisense transcripts after birth may be necessary before the phenotype progresses to a clinically obvious syndrome. In vitro data does support a role for TL-3 in neural processes.
In situ hybridization studies have shown IL-3 mRNA localized to astrocytes and microglial cells in the neocortex, cerebellum, hippocampus, subiculum and habenula.24 Rat astrocytes cultured in vitro secrete a For personal use only. on October 26, 2017 . by guest www.bloodjournal.org From protein with IL-3-like proper tie^,'^ and microglial cells, the macrophages of the CNS, proliferate in vitro in response to purified IL-3 or the IL-3-like activity secreted by cultured astrocyte^.'^.^^ IL-3 is also a trophic factor for central cholinergic neurons, promoting neurite outgrowth of cultured rat septal neurons.27 Lastly, a putative member of a family of protein tyrosine phosphatases that is believed to be involved in IL-3-induced signals has been cloned from an IL-3-dependent cell line and found to be expressed at high levels in brain tissue. 58 These findings suggest that a paracrine loop involving IL-3 may exist between neural and microglial elements in the CNS. Such a paracrine loop could have been disrupted in the AS-IL-3 transgenic mice due to decreased local production of IL-3; however, proof for this type of mechanism will require a better understanding of the function of IL-3 in the brain, and further analysis of IL-3 and IL-3R function as well as of microglial and neural elements in our transgenic mice. Interestingly, inactivation of the murine Wnt-l gene, either by targeted mutation or in the naturally-occurring mutant strain swaying ( S W ) , leads to abnormal anterior cerebellar development and a phenotype similar to that observed in the AS-IL-3 transgenic m i~e .~~.~' This gene encodes a secreted factor presumed to be involved in cerebellar development, thus there is precedent for the downmodulation or inactivation of a growth factor gene leading to abnormal neurologic function or development.
Another possible mechanism for both the B-cell lymphoproliferative and neurologic abnormalities is an indirect one, with decreased IL-3 production leading to immunosuppression and secondary infectious complications andor increased risk of malignant transformation. Patients with Tcell deficiencies resulting from human immunodeficiency virus infection or medications, such as cyclosporine, are predisposed both to B-cell lymphomas and to unusual CNS viral infections and neurologic dysfunction.6'.62 The lymphomas are often EBV-related, and can regress with improvement in immune function. Interestingly, IL-3 has been shown to suppress the outgrowth of EBV-transformed human Bcell lines in vitro." It also protects mice from acute herpes simplex virus en~ephalitis.6~ We were unable to detect an infectious agent as an etiology for the phenotypes in the AS-IL-3 mice. The syndromes were not transmissable to nontransgenic mice, and although several retroviruses have been shown to transform murine B cells in vitro,@ no RT activity was detected in symptomatic transgenic animals. In AS-IL-3 transgenic animals, we also did not detect alterations in the absolute number of mature T cells in the peripheral lymphoid organs, either before or following the onset of the B-cell lymphoproliferative syndrome.
In the present study, we have demonstrated the utility of in vivo antisense inhibition as a means of elucidating functions of hematopoietic growth factors. Transgenic mice expressing antisense IL-3 sequences and showing evidence of downmodulation of IL-3 production developed either a Bcell lymphoproliferative syndrome or neurologic dysfunction. AS-IL-3 transgenic mice did not exhibit hematopoietic abnormalities, suggesting that high levels of IL-3 are not required for normal hematopoiesis, but that appropriate expression of this cytokine may be required for regulation of B lymphopoiesis and maintenance of normal neurologic function. Although we cannot exclude the possibility that antisense inhibition of IL-3 has dysregulated the expression of an IL-3-like gene that is responsible for the observed phenotypes, the accumulated in vitro and in vivo data support a role for this cytokine in both of these physiologic processes. The generation of mice exhibiting a complete abrogation of IL-3 production as a consequence of targeted mutation of the IL-3 gene will be an important additional contribution to our understanding of the role of IL-3 in vivo, and will provide useful information regarding the consequences of downmodulation versus complete loss of function of this important hematopoietic growth factor. Limitations For personal use only. on October 26, 2017 . by guest www.bloodjournal.org From
